Michael F Chang

Dr. Michael F Chang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BJBinu V. John
Binu V. John
ELEleanor Love
Eleanor Love
BDBassam Dahman
Bassam Dahman
NKNargiza Kurbanova
Nargiza Kurbanova
VKVenkata Rajesh Konjeti
Venkata Rajesh Konjeti
MSMohammad S. Siddiqui
Mohammad S. Siddiqui

1 May 2015 in Gastroenterology Nursing
Verified
Journal Article
Closed access
LHLissi Hansen
Lissi Hansen
MLMichael C. Leo
Michael C. Leo
MCMichael F Chang
Michael F Chang
AZAtif Zaman
Atif Zaman
WNWillscott Naugler
Willscott Naugler
JSJonathan Schwartz
Jonathan Schwartz
Research on symptom distress experienced by patients with end-stage liver disease at the end of life is limited. The aims of the study were to describe presence, frequency, severity, and distress of symptoms in patients with end-stage liver disease toward the end of life and to describe the variability in psychological and physical symptom distress between and within patients over time. This study used a prospective, longitudinal descriptive design. Data were collected from 20 patients once a month for up to 6 months. Participants completed the Memorial Symptom Assessment Scale, which reports a total score, a Global Distress Index score, and a psychological and a physical distress score. Patients reported lack of energy, pain, difficulty sleeping, and feeling drowsy as the most frequent, severe, and distressing symptoms. Global Distress Index mean scores (measured on a 1-4 scale) ranged from 2.6 to 2.9 across time. There was notable variability in psychological and physical distress scores between and within patients across time. Gaining knowledge about the prevalent symptoms experienced by patients with end-stage liver disease and the trajectory of these symptoms is crucial for designing interventions that optimize well-being in patients with end-stage liver disease as they are approaching death.

27 August 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LHLissi Hansen
Lissi Hansen
MCMichael F Chang
Michael F Chang
SHShirin O Hiatt
Shirin O Hiatt
NDNathan F. Dieckmann
Nathan F. Dieckmann
KLKaren S Lyons
Karen S Lyons
CLChristopher S Lee
Christopher S Lee

1 March 2014 in Journal of Palliative Care
Verified
Journal Article
Open access
PDF file
LHLissi Hansen
Lissi Hansen
MLMichael C. Leo
Michael C. Leo
MCMichael F Chang
Michael F Chang
BZBetsy L. Zucker
Betsy L. Zucker
ASAnna Sasaki
Anna Sasaki
This prospective descriptive study investigated pain characteristics in 20 outpatients with end-stage liver disease (ESLD) who were approaching the end of life, described variability in pain between and within patients, and described the pharmacological and nonpharmacological pain management strategies used. The instruments we utilized were the Brief Pain Inventory (BPI) and the self-care behaviour (SCB) log for pain. Data were collected once a month over a six-month period. BPI severity of, and interference from pain mean scores ranged from 5.52 to 6.03 and 5.36 to 6.64, respectively. The top three pain-relieving behaviours reported by patients were “taking pain medication,” “taking a nap,” and “asking for help.” Pain medication intake differed between patients who were pursuing a liver transplant and those who were not eligible for one. If we are to effectively improve care for ESLD patients, it is essential that we understand the ways in which these patients experience pain and the pain management strategies they employ.

BPBrian Palen
Brian Palen
EMElizabeth Mattox
Elizabeth Mattox
KHKen He
Ken He
LBLauren A. Beste
Lauren A. Beste
JBJoleen Borgerding
Joleen Borgerding
EPElizabeth C. Parsons
Elizabeth C. Parsons
Sleep VA-ECHO (Veterans Affairs–Extension for Community Healthcare Outcomes) is a national telementorship program intended to improve knowledge about sleep disorders among non-specialty providers. The project goal was to describe the characteristics of Sleep VA-ECHO participants from primary care and their use of program-obtained knowledge in practice. Sleep VA-ECHO consisted of 10 voluntary, 75-min teleconference sessions combining didactics and case discussion. Out of 86 participants, 21 self-identified as primary care team members and completed a program evaluation. Participants self-reported their application of knowledge gained, including changes to practice as a result of program participation. These 21 participants represented 18 sites in 11 states and attended a median of 5.0 sessions. They included physicians (29%), nurse practitioners (24%), and registered nurses (24%). Nearly all participants (95%) reported using acquired knowledge to care for their own patients at least once a month; 67% shared knowledge with colleagues at least once a month. Eighty-five percent reported improved quality of sleep care for their patients, and 76% reported an expanded clinical skillset. The greatest self-reported change in practice occurred in patient education about sleep disorders (95%) and non-pharmacologic management of insomnia (81%).

30 January 2023 in Hepatology
Verified
Journal Article
Closed access
AAAdeyinka C. Adejumo
Adeyinka C. Adejumo
VYVera Yakovchenko
Vera Yakovchenko
TMTimothy R. Morgan
Timothy R. Morgan
PSPatrick Spoutz
Patrick Spoutz
LCLinda Chia
Linda Chia
SRShari Rogal
Shari Rogal
Background & Aims: This study aimed to evaluate quarterly trends in process and health outcomes among Veterans with cirrhosis and assess the factors associated with cirrhosis outcomes before and during the COVID-19 pandemic. Approach & Results: US Veterans with cirrhosis were identified using the Veterans Health Administration Corporate Data Warehouse. Quarterly measures were evaluated from September 30, 2018, through March 31, 2022, including twice yearly screening for hepatocellular carcinoma (HCC-6), new HCC, surveillance for or treatment of esophageal varices, variceal bleeding, all-cause hospitalization, and mortality. Joinpoint analyses were used to assess the changes in trends over time. Logistic regression models were used to identify the demographic and medical factors associated with each outcome over time. Among 111,558 Veterans with cirrhosis with a mean Model for End-stage Liver Disease-Sodium of 11±5, rates of HCC-6 sharply declined from a prepandemic peak of 41%, to a nadir of 28%, and rebounded to 36% by March 2022. All-cause mortality did not significantly change over the pandemic, but new HCC diagnosis, EVST, variceal bleeding, and all-cause hospitalization significantly declined over follow-up. Quarterly HCC diagnosis declined from 0.49% to 0.38%, EVST from 50% to 41%, variceal bleeding from 0.15% to 0.11%, and hospitalization from 9% to 5%. Rurality became newly, significantly associated with nonscreening over the pandemic (aOR for HCC−6=0.80, 95% CI 0.74 to 0.86; aOR for EVST=0.95, 95% CI 0.90 to 0.997). Conclusions: The pandemic continues to impact cirrhosis care. Identifying populations at the highest risk of care disruptions may help to address ongoing areas of need.